Sun Pharmaceutical Industries announced an investment of ₹500 crore to set up a pharmaceutical manufacturing facility in Assam, strengthening its domestic production capacity while creating significant employment opportunities in the region. The upcoming facility is expected to provide a major boost to the state’s industrial and healthcare manufacturing ecosystem.
Two-Phase Rollout Focused on Formulations
The company will execute the project in two phases, with the primary focus on establishing drug formulation manufacturing units to meet growing domestic demand. Confirming the development, Assam Chief Secretary Ravi Kota said the state government held discussions with senior Sun Pharma officials to facilitate the project’s smooth implementation. During the meeting, both sides reviewed key infrastructure requirements, including land availability, water supply, power connectivity, logistics access and skilled workforce support.
Strengthening Assam’s Pharma Manufacturing Ecosystem
The investment is expected to enhance Assam’s position as an emerging pharmaceutical manufacturing hub, while also supporting India’s broader push for localised drug production and supply chain resilience. With improved infrastructure and policy support, the project could attract additional investments into the state’s life sciences and healthcare sectors.
Focus on Sustainable Operations
Alongside capacity expansion, Sun Pharma has committed to adopting sustainable manufacturing practices at the new facility. The company plans to prioritise efficient water usage, renewable energy adoption and responsible waste management to minimise environmental impact. These measures will help ensure compliance with environmental norms and promote long-term operational sustainability. As reported by projectstoday.com, by combining investment, job creation and green manufacturing practices, Sun Pharma’s Assam plant is set to contribute to both regional economic growth and India’s expanding pharmaceutical production base.
